Second-trimester screening test for open neural tube defects. Order this test for PREGNANT FEMALE patients only. For males or non-pregnant females, refer to Alpha Fetoprotein, Serum (Tumor Marker) (0080428).
Quantitative Chemiluminescent Immunoassay
New York DOH Approval Status
Specimen must be drawn between 14 weeks, 0 days and 24 weeks, 6 days gestation.
Serum Separator Tube (SST) or Plain Red.
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Plasma. Hemolyzed specimens.
Submit with Order: Patient's date of birth, current weight, due date, dating method (US, LMP), number of fetuses present, patient's race, if the patient was diabetic at the time of conception, if there is a known family history of neural tube defects, if the patient is currently smoking, if the patient is taking valproic acid or carbamazepine (Tegretol), if this is a repeat sample, and the age of the egg donor if an in vitro fertilization.
After separation from cells: Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 1 year (Avoid repeated freeze/thaw cycles.)
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
This test is used to screen for fetal risk of Open Neural Tube Defect (i.e., spina bifida).
|Component Test Code*||Component Chart Name||LOINC|
|0080241||Estimated Due Date||11778-8|
|0080918||MoM for AFP||20450-3|
|0080920||Maternal Screen Interpretation||49586-1|
|0080924||Insulin Req Maternal Diabetes||44877-9|
|0080925||Family Hx Neural Tube Defect||8670-2|
|0080927||Number of Fetuses||11878-6|
|0080932||Maternal Age At Delivery||21612-7|
|3000263||Gestational Age Calculated at Collection||18185-9|
- AFP Maternal Screening
- AFP Neural Tube Defects
- Maternal Screening, AFP Single Marker